Put companies on watchlist
SHOP APOTHEKE EUROPE N.V.
ISIN: NL0012044747
WKN: A2AR94
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SHOP APOTHEKE EUROPE N.V. · ISIN: NL0012044747 · EQS - adhoc news (113 News)
Country: Netherlands · Primary market: Netherlands · EQS NID: 1631243
11 May 2023 07:14PM

SHOP APOTHEKE EUROPE and GALENICA: Antitrust clearances for joint venture granted


EQS-Ad-hoc: SHOP APOTHEKE EUROPE N.V. / Key word(s): Joint Venture/Capital Increase
SHOP APOTHEKE EUROPE and GALENICA: Antitrust clearances for joint venture granted

11-May-2023 / 19:14 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


SHOP APOTHEKE EUROPE and GALENICA: Antitrust clearances for joint venture granted

Sevenum, the Netherlands, 11 May 2023 Redcare Pharmacy N.V. (formerly SHOP APOTHEKE EUROPE N.V.) and GALENICA AG announce that they have received clearances from the relevant antitrust authorities for the incorporation of their announced joint venture in the Swiss market (the "Transaction").

The antitrust clearances were conditions precedent for the execution of the Transaction, under which the business activities of shop-apotheke.ch and Mediservice AG will be merged into a joint company.

Following the approval, the Transaction will now be closed as planned on short notice, expected to be on 16 May 2023. Furthermore, the capital increase to be carried out as part of the Transaction is expected to be concluded by the end of June 2023 at the latest.

 



End of Inside Information

11-May-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SHOP APOTHEKE EUROPE N.V.
Erik de Rodeweg 11-13
5975 WD Sevenum
Netherlands
Phone: 0800 - 200 800 300
Fax: 0800 - 90 70 90 20
E-mail: Investor.Relations@shop-apotheke.com
Internet: www.shop-apotheke-europe.com
ISIN: NL0012044747, DE000A19Y072
WKN: A2AR94, A19Y07
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1631243

 
End of Announcement EQS News Service

1631243  11-May-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1631243&application_name=news&site_id=boersengefluester_html
Visual performance / price development - SHOP APOTHEKE EUROPE N.V.
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.